Abstracts tagged "renal disease and SRI"

Abstract Number: 860 • 2019 ACR/ARP Annual Meeting
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
Luiz Sergio Guedes Barbosa ¹, Amit Saxena ², Ellen M Ginzler ³, Richard Furie⁴, David D'Cruz ⁵, Susan Burriss ⁶, Jennifer Gilbride ⁷, Michelle Miller ⁶, James Groark ⁶, David Roth ⁶ and Beulah Ji ⁸, ¹NUTEC - Núcleo de Terapia Especializada em Cancerologia, Cuiaba, Brazil, ²New York University School of Medicine, New York, NY, ³State University of New York Downstate Medical Center, Brooklyn, NY, ⁴Northwell Health, Great Neck, NY, ⁵The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁶GSK, Collegeville, PA, ⁷GSK, Stevenage, Hertfordshire, United Kingdom, ⁸GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Black patients have more severe SLE and more frequent lupus nephritis vs other racial groups. Efficacy and safety of intravenous (IV) belimumab was demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].